Afeng Yang
Impact in
-
- Immunotherapy and Immune Responses
- Immune cells in cancer
- Biomaterials top 10%
- Nanoparticle-Based Drug Delivery
Papers in
-
- Immunotherapy and Immune Responses 5
- Immune cells in cancer 3
-
- Nanoplatforms for cancer theranostics 8
- Co-authors
- Xia Dong (10 shared papers)Feng Lv (10 shared papers)Deling Kong (5 shared papers)Jie Liang (3 shared papers)Zhiyong Qian (2 shared papers)Yun Xiu Bai (4 shared papers)Dunwan Zhu (5 shared papers)Deling Kong (2 shared papers)
- Journals
- Biomaterials (2 papers)Acta Biomaterialia (2 papers)ACS Applied Materials & Interfaces (2 papers)Chemical Engineering Journal (1 paper)Nanomedicine Nanotechnology Biology and Medicine (1 paper)
- Partner nations
- ChinaUnited KingdomUnited States
In The Last Decade
Afeng Yang
10 papers receiving 464 citations
Peers
Comparison fields: 5 of 56
- Immunology 188
- Biomaterials 120
- Molecular Medicine 42
- Biomedical Engineering 308
- Pharmaceutical Science 22
Countries citing papers authored by Afeng Yang
This map shows the geographic impact of Afeng Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Afeng Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Afeng Yang more than expected).
Fields of papers citing papers by Afeng Yang
This network shows the impact of papers produced by Afeng Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Afeng Yang. The network helps show where Afeng Yang may publish in the future.
Co-authors
The 20 scholars most cited alongside Afeng Yang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 118 | |
| 2 | 2019 | 89 | |
| 3 | 2019 | 64 | |
| 4 | 2018 | 52 | |
| 5 | 2021 | 45 | |
| 6 | 2021 | 33 | |
| 7 | 2018 | 27 | |
| 8 | 2018 | 19 | |
| 9 | 2022 | 14 | |
| 10 | 2018 | 8 |
About Afeng Yang
Afeng Yang is a scholar working on Immunology, Biomedical Engineering, Radiology, Nuclear Medicine and Imaging, Molecular Medicine and Pharmaceutical Science, having authored 10 papers that have together received 469 indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (8 papers), Immunotherapy and Immune Responses (5 papers), Immune cells in cancer (3 papers), Photodynamic Therapy Research Studies (2 papers), Monoclonal and Polyclonal Antibodies Research (2 papers), Contact Dermatitis and Allergies (1 paper), Curcumin's Biomedical Applications (1 paper) and Advancements in Transdermal Drug Delivery (1 paper). The work is most often cited by research in Immunology (188 citations), Biomaterials (120 citations), Molecular Medicine (42 citations), Biomedical Engineering (308 citations) and Pharmaceutical Science (22 citations). Afeng Yang has collaborated with scholars based in China, United Kingdom and United States. Frequent co-authors include Xia Dong, Feng Lv, Deling Kong, Jie Liang, Zhiyong Qian, Yun Xiu Bai, Dunwan Zhu, Deling Kong, Jie Liang and Tianjun Liu. Their work appears in journals such as Biomaterials, Acta Biomaterialia, ACS Applied Materials & Interfaces, Chemical Engineering Journal and Nanomedicine Nanotechnology Biology and Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.